Sectors:
HealthcareAndrew Aijian
Biography
Andrew is a Sr. Partner at DeciBio Consulting, with over 15 years experience in life science research and consulting. At DeciBio, Andrew serves as the head of the pharma practice, and works with stakeholders throughout the precision medicine ecosystem, including pharma, diagnostics companies, research tools manufacturers, and clinical and research services providers to optimize the development and delivery of precision medicines. Andrew supports pharma with all aspects of precision medicine strategy, including global landscape assessments, market sizing and forecasting, biomarker and diagnostic technology and commercial assessments, patient treatment and diagnostic journey mapping, and strategic partnering and M&A. Andrew regularly publishes, presents, and lectures on key topics in precision medicine, with particular expertise in oncology biomarkers and diagnostic technologies.
At DeciBio Andrew serves as the Partner lead of DeciBio’s marketing team and syndicated reports business, overseeing the expansion and diversification of DeciBio’s market-leading reports portfolio. Prior to DeciBio, Andrew received his Ph.D. in Biomedical Engineering from the University of California, Los Angeles, and his B.S. in Chemical and Biomolecular Engineering from the University of Notre Dame.
Area of Expertise
Cancer immunotherapy, emerging technology development and commercialization, Personalized/precision medicine, Disruptive healthcare products and services, regenerative medicine
Group Overview
As the pace of innovation in precision therapies accelerates, so do the challenges in bringing these transformative therapies to patients. Navigating evolving clinical trial, regulatory, manufacturing, and market access landscapes requires precise market insights and novel strategies.
Client examples include:
Biopharma Genomic Testing Market Research
Clinical, Genomic, and Pathology Real-World Data (RWD) Market Landscape Assessment
Internal Lab Buildout Strategy
Synthetic mRNA Production Landscape Assessment
Firm Overview
DeciBio is a strategy consulting and market intelligence firm serving clients across the precision medicine ecosystem.
DeciBio’s mission
To accelerate the adoption and impact of precision medicine
Precision medicine is a complex and rapidly-evolving field, requiring focus and attention to detail in order to keep up with the pace of innovation. With DeciBio’s specialized team of life science experts, DeciBio focuses on the precision medicine space.
Working across the entire precision medicine value chain—from early-stage research to commercialization and the patient journey—gives DeciBio a uniquely comprehensive perspective. Consequently, DeciBio understands how market developments propagate throughout the precision medicine ecosystem.
DeciBio Consulting is a boutique strategy consulting firm focusing on the life science industry. DeciBio’s mission is to provide the strategic insights that accelerate the development, adoption, and accessibility of personalized medicine.
Headquartered in Los Angeles, CA, DeciBio serves clients and customers across the globe, ranging from incubator-stage startups to Fortune 500 life science corporations. DeciBio addresses business solutions that range from market landscape analyses to full commercial strategies, including organic and inorganic growth opportunities (commercial due diligences). DeciBio’s work is typically supported by a mix of primary and secondary research leveraging Dexter, its in-house expert network, and DeciBio Analytics’ proprietary data intelligence products.
DeciBio’s Analytics division offers numerous data products to support strategic insights, including in clinical diagnostics (the DxBooks), immuno-oncology (the I/O BioMAP), omics market segmentation (the MarketBooks), and the entire life sciences industry (BioTrack).
Internal teams such as the Culture Committee, Women* in Consulting, and Gays in Consulting enrich the employee experience. DeciBio’s Social Impact board and the DeciBio Impact Lab work collaboratively across divisions and externally to uproot discrimination and increase access to precision medicine.